Nucleoside-Based Phospholipids and Their Liposomes Formed in Water

Seung Kyu Choi, Tran Khac Vu, Jin Mi Jung, Su Jeong Kim, Hun Rok Jung, Taihyun Chang, and Byeang Hyean Kim^{*[a]}

Phospholipids and liposomes have been the subjects of considerable attention because of their importance in biological systems. We have efficiently synthesized novel nucleoside-based phospholipids in six-step sequences starting from their corresponding nucleosides. These nucleoside-based phospholipids self-assemble into liposome-like structures in aqueous solutions. We have analyzed the structures of these liposomes by dynamic light scattering, transmission electron microscopy, and confocal microscopy.

Introduction

Phospholipids are major constituents of cell membranes.^[1] When certain phospholipids are dispersed in water, spherical bilayer vesicles, known as liposomes, form spontaneously. Modification of different parts of a phospholipid's structure can affect its activity in biological processes.^[2] Such modifications are generally limited to its hydrophobic tail and hydrophilic head groups, or to structural variants of its glycerol unit.^[3] Recently, the synthesis and physical characterization of novel carbohydrate-based phospholipids have been reported; these phospholipids self-assemble into liposome-like structures in aqueous solution.^[4] An example is the synthesis and physicochemical study of one such uridine-based phospholipid.^[5] The authors demonstrated that this modified phospholipid exhibits physical properties that differ from those of its glycerolbased analogues; this indicates the importance that the constitution of the backbone has for the nature of the bilayer structure. The morphologies of some phosphatidyl nucleosides have already been reported by Yanagawa^[6] and Luisi,^[7] who were the first to investigate the self-association of this family of lipids. Intrigued by these interesting results, we have designed and synthesized novel nucleoside-based phospholipids. Nucleoside phospholipids have one more structural element for molecular recognition-namely, the nucleobase-than carbohydrate phospholipids.^[4,8]

Results and Discussion

Here we present an efficient synthesis of novel phospholipids based on the nucleosides uridine, adenosine, and inosine (Scheme 1), their molecular recognition, and the morphologies of their self-assembled liposome structures in aqueous solution. Modifications of phospholipid structure are currently limited to the hydrophobic tails, hydrophilic headgroups, and structural variations of the glycerol backbone.^[3],9] Consequently, alteration of the conventional glycerol backbone by complete substitution provides new opportunities for: 1) assessing supramolecular structure formation, and 2) attaching macromolecules or ligands for biological targeting.

The first step in the synthesis of the nucleoside-based phospholipids involved protecting the primary hydroxy groups of uridine, adenosine, and inosine with 4-methoxytrityl chloride (MMTrCl) to yield 1 (97%), 2 (62%), and 3 (74%), respectively, after chromatography on silica gel. Next, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide·HCl (EDC)/N,N-dimethylaminopyridine (DMAP) coupling individually with decanoic, lauric, myristic, palmitic, and stearic acids in CH₂Cl₂ afforded a series of diesters. Without purification, each of these intermediates was dissolved in 80% aqueous AcOH at 60°C to remove its protecting groups. Compounds 4 (88-98% from 1), 5 (85-98% from 2), and 6 (77-88% from 3) were purified by chromatography on silica gel, and compounds 7-9 were then prepared by treating 4-6 with 2-chloro-1,3,2-dioxaphospholane, oxidizing the intermediate phosphorus(111) compounds with Br₂ to give the phosphorus(v) products, and subsequently introducing the phosphocholine group by treatment with Me₃N. Compounds 7-9 were isolated after chromatography on silica gel. The overall yields for the last three steps (d-f) were 37-58% (7), 18-33% (8), and 19-27% (9).^[10]

The first feature of nucleoside-based phospholipids that we studied was the hydrodynamic radii of their vesicles. We heated 0.3 mm aqueous solutions of each nucleoside-based phospholipid to 60 °C and then sonicated them for 30 min.⁽¹¹⁻¹³⁾ The liposomes could then be prepared by using a high-pressure extrusion technique, which allows liposomes of small and uniform size to be obtained. Extrusion of the nucleoside-based phospholipids five times through a 200 nm poly-

 [[]a] S. K. Choi, Dr. T. K. Vu, J. M. Jung, Dr. S. J. Kim, H. R. Jung, Prof. Dr. T. Chang, Prof. Dr. B. H. Kim Department of Chemistry, Division of Molecular and Life Sciences Pohang University of Science and Technology San 31 Hyoja Dong, Pohang 790–784 (South Korea) Fax: (+82) 54-279-3399 E-mail: bhkim@postech.ac.kr



Scheme 1. Reagents and conditions: a) MMTr-Cl, pyridine, RT, 9 h (uridine), 20 h (adenosine), 18 h (inosine). b) EDC, DMAP, decanoic/lauric/myristic/palmitic/stearic acid, CH₂Cl₂, RT, 4 h. c) 80% acetic acid, 60°C, 3 h. d) DIPEA, 2-chloro-1,3,2-dioxaphospholane, THF, RT, 15 min. e) Br₂, 0°C, 1 h. f) 40% Me₃N, CHCl₃/iPrOH/CH₃CN (3:5:5), RT, 3 days.

carbonate filter at 25 °C provided vesicles with average particle hydrodynamic radii of 39–70 nm when analyzed with a dynamic light scattering (DLS) apparatus. Generally, the hydrodynamic radii of the vesicles increase with increasing length of their alkyl chains.

We next used transmission electron microscopy (TEM) to observe the morphologies of the vesicles. We prepared liposomes using a buffer solution comprising 30 mм Tris/HCl, 20 mм KCl, and 0.1 mm EDTA that was adjusted to pH 8 at room temperature. Again, the lipid dispersion (0.3 mm) was passed repeatedly through a 200 nm polycarbonate filter before being analyzed by TEM, by the negative-staining technique;^[14, 15] Figure 1 displays the resulting micrographs. From these images, it is clear that the liposomes aggregate into spherical closed liposomes. In the previous studies performed by Yanagawa^[6] and Luisi,^[7] phosphatidyl nucleosides were demonstrated to aggregate and to have morphologies such as super-helical strands, rings, and flat disks. We observed the same spherical morphologies for all the liposomes of nucleoside-based phospholipids, even though they feature different nucleobases. From these results, we conclude that the morphologies of the nucleoside-



Figure 1. TEM images of negatively stained liposomes formed from dispersions of nucleoside-based phospholipids (0.3 mm) prepared in Tris-HCI (30 mm)/KCI (20 mm)/EDTA (0.1 mm) at pH 8. Micrographs of: a) adenosine-based liposome **8b**, and b) uridine-based liposome **7b**.

FULL PAPERS

based phospholipids are the same (i.e., independent of the nucleobase), but the most significant effect on the liposomes' structures arises from changes in the nature of the nonpolar alkyl chain. The longer the alkyl chains they possess, the greater bending rigidity. Again, this finding stresses that the molecular structure of the lipid has an important effect on the morphology and physical properties of the aggregates.

Next, to confirm the location of nucleobases within the liposomes and to study their molecular recognition properties, we prepared liposomes through the self-assembly of **7**, **8**, and **9**. To study these effects, we chose to

treat the dispersions of liposomes with functionalized dyes that should be specific for certain base sequences, and to view their association by confocal microscopy. Because of the resolution of confocal microscopy (> ca. 1 μ m), it was necessary for us to prepare relatively large phospholipid vesicles.[16,17] To obtain these samples, we heated 0.3 mm aqueous solutions of nucleoside-based phospholipids to 60 °C and then sonicated them for 30 min. The complementary base pairing of nucleic acids is a biological recognition process based on hydrogen bonding.^[18] We wondered whether the bases of the nucleosides were presented at the surfaces of the spherical vesicles and, if so, whether they were capable of hydrogen bonding with short oligonucleotide sequences. To answer these questions, we synthesized a fluorescein isothiocyanate-2'-deoxynucleoside trimer (FITC-trimer, 10) and a hexachlorofluorescein-2'deoxynucleoside trimer (Hex-trimer, 11), from commercially available phosphoamidite monomers, using a DNA synthesizer (Scheme 2).

Figure 2 indicates that such hydrogen bonding indeed occurs and, additionally, that it occurs in a selective manner. Figures 2a and b indicate that the liposome formed from 7c binds both to the FITC-linked and to the Hex-linked adenosine trimers (i.e., both of these dyes can be accommodated by the liposome). To rule out the possibility that this binding might be indiscriminate (e.g., that it is the dye that binds and not the adenosine trimer unit), we irradiated a solution containing the liposome of 7c and a mixture of the dyed oligonucleotide trimers FTIC-AAA, Hex-CCC, and Hex-GGG. Figure 2c indicates that this liposome displays only green fluorescence, while Figure 2d indicates that the liposome does not display red fluorescence from this mixture, which suggests that the liposome selectively recognizes the AAA unit, rather than the CCC unit or the GGG unit (i.e., that there is selective hydrogen bonding between the uracil and adenine bases). From these initial finding, we believe that liposomes of uridine-based phospholipids should recognize the poly(A) tail of mRNA.^[19]

CHEMBIOCHEM



Scheme 2. Fluorescein-tagged 2'-deoxynucleoside trimers.



Figure 2. Confocal microscopy images of uridine-based liposomes formed from **7***c* associating on a glass surface with labeled oligonucleotide trimers. a) Mixture of the liposome of **7***c* and FITC-AAA, irradiated with laser light (h_{ex} = 488 nm) that causes green fluorescence of the FITC moieties. b) Mixture of the liposome of **7***c* and Hex-AAA irradiated with laser light (h_{ex} = 543 nm) that causes red fluorescence of the Hex moieties. c) Mixture of the liposome of **7***c* and FITC-AAA, Hex-CCC, and Hex-GGG, irradiated simultaneously both at 488 and at 543 nm. d) Mixture of the liposome of **7***c* and Hex-GGG.

Conclusion

These nucleoside-based phospholipids have large backbones that increase the spacing between the head and tail units, and they have increased hydrodynamic radii relative to other phospholipids with different backbones. Like the phosphatidyl nucleosides,^[6,7] the monomers of these nucleoside-based phospholipids can aggregate together, but the morphologies of these aggregates differ substantially. The liposomes of these nucleoside-based phospholipids have spherical morphologies, which we believe are affected primarily by the lengths of the alkyl chains of nucleoside-based phospholipid monomers. The ability of the liposomes to recognize oligonucleotides through hydrogen bonding makes them attractive alternatives to glycerol- and carbohydratebased phospholipid liposomes. These results may provide new insight into the tailoring of vesicle properties for specific pharmaceutical and industrial applications.

Experimental Section

Materials and instruments: All starting materials were obtained from commercial suppliers and were used without further purification. Tetrahydrofuran (THF) was distilled under nitrogen from sodium/benzophenone,

and CH₂Cl₂ and pyridine were distilled under nitrogen from calcium hydride, immediately prior to use. Reactions were executed under an inert atmosphere of dry argon, and the glassware was flamedried under vacuum. Flash chromatography was performed on Merck silica gel 60 (230-400 mesh; ASTM). Melting points are uncorrected and were obtained with an Electrothermal IA 9000 series apparatus. Infrared (IR) spectra were recorded on a Bruker model FT-IR PS55 + spectrometer. Low- and high-resolution FAB mass spectra were obtained on a Jeol JMS-AX505WA (FAB) spectrometer. An LSM510 (Zeiss) apparatus was used for confocal microscopy. A Malvern 4700 series photon correlation spectrometer was used for dynamic light scattering (DLS) to measure particle size. Transmission electron microscopy (TEM) measurements were obtained on a Hitachi-7600 instrument. ¹H, ¹³C, and ³¹P NMR spectra were obtained on a Bruker Aspect 3000 spectrometer. Chemical shifts in ¹H and ¹³C NMR spectra are reported in parts per million downfield of tetramethylsilane (TMS) as the internal standard. ³¹P NMR chemical shifts are reported in ppm downfield relative to phosphoric acid as the external standard. Coupling constants are reported in hertz.

Uridine-based phospholipids

5'-O-(4-Methoxytrityl)uridine (1): MMTr-Cl (1.55 g, 5.03 mmol) was added to a solution of uridine (1.02 g, 4.19 mmol) in dry pyridine (50 mL) and the mixture was stirred at room temperature for 9 h. The solvent was evaporated under high vacuum, and the resultant oil was dissolved in CH₂Cl₂ and washed with water. The organic layer was separated and then dried (Na₂SO₄). Chromatographic purification (SiO₂; CH₂Cl₂/MeOH 50:1) yielded **1** (2.11 g, 97%). m.p. 117.2–119.0 °C; ¹H NMR (300 MHz, CDCl₃): δ = 8.01 (d, *J*=9.0 Hz, 1 H), 7.40–6.82 (m, 15 H), 5.89 (d, *J*=3.0 Hz, 1 H), 5.32 (t, *J*=7.5 Hz, 1 H), 4.44 (t, *J*=6.0 Hz, 1 H), 4.35 (t, *J*=3.0 Hz, 1 H), 4.17–4.15 (m, 1 H), 3.76 ppm (s, 3 H); ¹³C NMR (75 MHz, CDCl₃): δ = 164.2, 158.9, 151.4, 144.1, 143.9, 140.6, 134.9, 130.7, 128.6, 128.5, 128.2, 127.5,

113.5, 102.5, 90.5, 87.5, 83.8, 75.6, 69.8, 62.1, 55.4 ppm; IR (NaCl): $\tilde{\nu} = 3392$, 3059, 2930, 1697, 1509, 1463, 1393, 1252 cm⁻¹; MS-FAB (*m/z*): found 517.14 [*M*+H]⁺; C₂₉H₂₈N₂O₇ calcd 517.19.

2',3'-O-Didecanoyluridine (4a)—General Procedure: Decanoic acid (1.78 g, 10.4 mmol) was added to a solution of 1 (2.15 g, 4.17 mmol), EDC (2.00 g, 10.4 mmol), and DMAP (615 mg, 5.00 mmol) in dry CH₂Cl₂ (40 mL). The mixture was stirred at room temperature for 4 h, extracted with water, and then concentrated to dryness. The residue was dissolved in acetic acid (80%, 50 mL) and was then heated at 60 °C for 3 h. The reaction mixture was washed with water and CH₂Cl₂, the organic layer was separated and dried (Na₂SO₄), and the solvent was evaporated under reduced pressure. Chromatographic purification (SiO₂; CH₂Cl₂/MeOH 60:1) afforded 4a (2.23 g, 96%). m.p. 98.5-106.5 °C; ¹H NMR (300 MHz, CDCl₃): $\delta = 8.45$ (s, 1 H), 7.71 (d, J = 9.0 Hz, 1 H), 6.04 (t, J = 3.0 Hz, 1 H), 5.79 (dd, $J_1 = 6.0$ Hz, $J_2 = 3.0$ Hz, 1 H), 5.49 (t, J = 4.5 Hz, 2 H), 4.20 (d, J=6.0 Hz, 1 H), 3.99-3.85 (m, 2 H), 2.40-2.31 (m, 4 H), 1.67-1.57 (m, 5H), 1.27 (br, 24H), 0.89 ppm (t, J=7.5 Hz, 6H); ¹³C NMR $(75 \text{ MHz}, \text{ CDCl}_3)$: $\delta = 172.8$, 172.4, 162.5, 150.2, 140.5, 109.5, 103.2, 88.0, 83.5, 72.7, 70.9, 61.9, 34.0, 33.8, 31.8, 29.4, 29.2, 29.1, 29.0, 24.7, 22.0, 14.0 ppm; IR (NaCl): ṽ = 3452, 2925, 2854, 1748, 1652, 1384, 1269 cm⁻¹; MS-FAB (*m/z*): found 553.30 [*M*+H]⁺; C₂₉H₄₈N₂O₈ calcd 552.70.

2',3'-O-Dilauroyluridine (**4b**): Yield: 89%. m.p. 105.8–106.5 °C; ¹H NMR (300 MHz, CDCl₃): δ =7.73 (d, J=9.0 Hz, 1 H), 6.03 (t, J= 3.0 Hz, 1 H), 5.78 (d, J=9.0 Hz, 1 H), 5.47 (d, J=3.0 Hz, 2 H), 4.21 (s, 1 H), 3.97–3.89 (m, 2 H), 2.39–2.30 (m, 4 H), 1.27 (br, 32 H), 0.88 ppm (t, J=6.0 Hz, 6 H); ¹³C NMR (75 MHz, CDCl₃) δ =172.8, 172.4, 162.5, 150.2, 140.5, 109.4, 103.2, 88.0, 83.5, 72.8, 70.8, 61.9, 34.0, 33.8, 31.9, 29.6, 29.4, 29.3, 29.2, 29.1, 29.0, 24.8, 24.7, 22.6, 14.0 ppm; IR (NaCl): $\tilde{\nu}$ =3479, 2955, 2850, 1739, 1653, 1386, 1255 cm⁻¹; MS-FAB (*m/z*): found 609.40 [*M*+H]⁺; C₃₃H₅₆N₂O₈ calcd 609.40.

2',3'-O-Dimyristoyluridine (**4***c*): Yield: 98%. m.p. 104.0–105.2°C; ¹H NMR (300 MHz, CDCl₃): δ =7.71 (d, *J*=9.0 Hz, 1H), 6.03 (d, *J*= 6.0 Hz, 1H), 5.78 (d, *J*=9.0 Hz, 1H), 5.47 (d, *J*=6.0 Hz, 2H), 4.21 (s, 1H), 3.96–3.81 (m, 2H), 2.39–2.30 (m, 4H), 1.66–1.59 (m, 4H), 1.26 (br, 40 H), 0.88 ppm (t, *J*=6.0 Hz, 6H); ¹³C NMR (75 MHz, CDCl₃): δ = 173.5, 173.1, 163.1, 150.8, 141.2, 103.9, 88.7, 84.2, 73.5, 71.5, 62.6, 34.7, 34.5, 32.6, 30.3, 30.2, 30.0, 29.9, 29.8, 29.7, 25.5, 25.4, 23.4, 14.7 ppm; IR (NaCl): $\tilde{\nu}$ =3454, 2954, 2850, 1738, 1652, 1386, 1255 cm⁻¹; MS-FAB (*m*/*z*): found 665.40 [*M*+H]⁺; C₃₇H₆₄N₂O₈ calcd for 665.47.

2',3'-O-Dipalmitoyluridine (**4***d*): Yield: 96%. m.p. 111.6–112.7 °C; ¹H NMR (300 MHz, CDCl₃): δ =7.74 (d, J=9.0 Hz, 1 H), 6.05 (t, J= 4.5 Hz, 1 H), 5.79 (d, J=9.0 Hz, 1 H), 5.47 (d, J=3.0 Hz, 2 H), 4.20 (s, 1 H), 3.90 (dd, J₁=7.5 Hz, J₂=3.0 Hz, 2 H), 2.39–2.29 (m, 4 H), 1.63– 1.58 (m, 4 H), 1.26 (br, 48 H), 0.88 ppm (t, J=6.0 Hz, 6 H); ¹³C NMR (75 MHz, CDCl₃): δ =173.5, 173.1, 163.3, 150.9, 141.3, 110.1, 103.8, 88.6, 84.2, 73.6, 71.6, 62.6, 34.7, 34.5, 32.6, 30.4, 30.3, 30.2, 30.0, 29.9, 29.8, 29.7, 25.5, 25.4, 23.4, 14.7 ppm; IR (NaCl): $\hat{\nu}$ =3421, 2917, 2849, 1652 cm⁻¹; MS-FAB (*m*/*z*): found 721.50 [*M*+H]⁺; C₄₁H₇₂N₂O₈ calcd 721.51.

2',3'-O-Distearoyluridine (**4e**): Yield: 96%. m.p. 111.7–112.7 °C; ¹H NMR (300 MHz, CDCl₃): δ =7.71 (d, J=6.0 Hz, 1H), 6.85 (d, J= 9.0 Hz, 1H), 6.03 (t, J=3.0 Hz, 1H), 5.78 (d, J=6.0 Hz, 1H), 5.48 (t, J=3.0 Hz, 1H), 4.21 (s, 1H), 4.00–3.86 (m, 2H), 2.40–2.31 (m, 5H), 1.26 (br, 56H), 0.89 ppm (t, J=6.0 Hz, 6H); ¹³C NMR (75 MHz, CDCl₃): spectrum not obtained because of poor solubility; IR (NaCl): $\tilde{\nu}$ =3421, 2917, 2849, 1645 cm⁻¹; MS-FAB (*m*/*z*): found 799.60 [*M*+Na]⁺; C₄₅H₈₀N₂O₈ calcd 799.59. 5'-O-Phosphatidylcholine-2',3'-O-didecanoyluridine (7 a)—General Procedure: 2-Chloro-1,3,2-dioxaphospholane (245 µL, 2.75 mmol) was added to a solution of 4a (1.01 g, 1.83 mmol) and diisopropylethylamine (384 μ L, 2.20 mmol) in dry THF (20 mL), and the mixture was then stirred for 15 min at room temperature. Br₂ (282 μ L, 5.50 mmol) in dry THF (20 mL) was slowly added while stirring at 0°C for 1 h. The solvent was evaporated, and the residue was dissolved in CHCl₃/iPrOH/CH₃CN (3:5:5). Aqueous trimethylamine (40%, 10 mL) was added. The mixture was stirred for 3 days at room temperature, and the solvents were then evaporated. Purification was performed by flash chromatography (SiO₂; CH₂Cl₂/ MeOH/H₂O 14:5:0.1 to 140:55:8). Silica gel was removed by filtration through celite, and 7a was obtained upon evaporation of the solvent (668 mg, 51%). m.p. >152.3 °C (dec.); ¹H NMR (300 MHz; CDCl₃/CD₃OD 1:1): $\delta = 7.86$ (d, J = 9.0 Hz, 1 H), 6.22 (d, J = 6.0 Hz, 1 H), 5.92 (d, J=9.0 Hz, 1 H), 5.48 (d, J=6.0 Hz, 1 H), 5.31 (t, J=6.0 Hz, 1 H), 4.47 (s, 2 H), 4.28 (s, 1 H), 4.20 (s, 2 H), 3.71 (s, 2 H), 3.23 (s, 9H), 2.38 (t, J=6.0 Hz, 2H), 2.28 (t, J=6.0 Hz, 2H), 1.62-1.54(m, 5 H), 1.26 (br, 24 H), 0.86 ppm (t, J=6.0 Hz, 6 H); ¹³C NMR (75 MHz; CDCl₃/CD₃OD 1:1): δ = 173.2, 172.9, 165.2, 151.1, 141.2, 103.2, 85.9, 82.5, 82.4, 73.2, 71.3, 66.7, 65.2, 59.7, 54.5, 34.1, 33.8, 31.9, 29.5, 29.3, 29.2, 29.1, 24.9, 24.7, 22.7, 13.9 ppm; ³¹P NMR (121 MHz; CDCl₃/CD₃OD 1:1): $\delta = -0.5845$ ppm; IR (NaCl): $\tilde{\nu} = 3446$, 2955, 2853, 1739, 1652, 1617, 1457, 1378 cm⁻¹; MS-FAB (*m/z*): found 718.40 [*M*+H]⁺; C₃₄H₆₀N₃O₁₁P calcd 718.40; HRMS-FAB (*m/z*): found 718.4047 [*M*+H]⁺; C₃₄H₆₀N₃O₁₁P calcd 718.4044.

5'-O-*Phosphatidylcholine-2'*,3'-O-*dilauroyluridine* (**7***b*): Yield: 42%. m.p. >145.3 °C (dec.); ¹H NMR (300 MHz; CDCl₃/CD₃OD 1:1): δ = 7.91 (d, *J* = 9.0 Hz, 1H), 6.24 (d, *J* = 6.0 Hz, 1H), 5.92 (d, *J* = 9.0 Hz, 1H), 5.50 (dd, *J*₁ = 6.0 Hz, *J*₂ = 3.0 Hz, 1H), 5.32 (t, *J* = 7.5 Hz, 1H), 4.54 (s, 2H), 4.31 (s, 1H), 4.25 (s, 2H), 3.73 (s, 2H), 3.24 (s, 9H), 2.39 (t, *J* = 7.5 Hz, 2H), 1.63–1.55 (m, 5H), 1.27 (br, 32H), 0.87 ppm (t, *J* = 6.0 Hz, 6H); ¹³C NMR (75 MHz; CDCl₃/CD₃OD 1:1): δ = 172.9, 172.6, 165.2, 150.9, 141.1, 102.8, 85.8, 82.4, 73.1, 71.3, 66.6, 65.1, 59.6, 54.3, 31.8, 29.5, 29.4, 29.3, 29.2, 29.0, 28.9, 24.7, 24.5, 22.5, 13.9 ppm; ³¹P NMR (121 MHz; CDCl₃/CD₃OD 1:1): δ = -0.4853 ppm; IR (NaCl): $\hat{ν}$ = 3448, 2955, 2853, 1739, 1652, 1457, 1378, 1244 cm⁻¹; MS-FAB (*m/z*): found 774.46 [*M*+H]⁺; C₃₈H₆₈N₃O₁₁P calcd 774.4670.

5'-O-*Phosphatidylcholine-2'*,3'-O-*dimyristoyluridine* (**7**c): Yield: 37%. m.p. > 147.4 °C (dec.); ¹H NMR (300 MHz; CDCl₃/CD₃OD 1:1): δ = 7.75 (d, *J* = 9.0 Hz, 1 H), 6.08 (d, *J* = 6.0 Hz, 1 H), 5.78 (d, *J* = 9.0 Hz, 1 H), 5.35 (dd, *J*₁ = 6.0 Hz, *J*₂ = 3.0 Hz, 1 H), 5.18 (t, *J* = 6.0 Hz, 1 H), 4.38 (s, 2 H), 4.16 (s, 1 H), 4.12 (s, 2 H), 3.58 (s, 2 H), 3.08 (s, 9 H), 2.25 (t, *J* = 7.5 Hz, 2 H), 2.14 (t, *J* = 7.5 Hz, 2 H), 1.48–1.40 (m, 5 H), 1.12 (br, 40 H), 0.72 ppm (t, *J* = 6.0 Hz, 6H); ¹³C NMR (75 MHz; CDCl₃/CD₃OD 1:1): δ = 172.9, 172.7, 165.3, 151.0, 141.2, 102.9, 85.7, 82.3, 73.1, 71.3, 66.5, 65.2, 59.6, 54.3, 31.8, 29.6, 29.4, 29.3, 29.2, 29.1, 29.0, 24.8, 24.5, 22.5, 13.8 ppm; ³¹P NMR (121 MHz; CDCl₃/CD₃OD 1:1): δ = -0.5202 ppm; IR (NaCl): $\tilde{\nu}$ = 3452, 1749, 1652, 1456 cm⁻¹; MS-FAB (*m*/*z*): found 830.40 [*M*+H]⁺; C₄₂H₇₆N₃O₁₁P calcd 830.5296.

5'-O-Phosphatidylcholine-2',3'-O-dipalmitoyluridine (**7 d**): Yield: 53 %. m.p. > 146.5 °C (dec.); ¹H NMR (300 MHz; CDCl₃/CD₃OD 1:1): δ = 7.91 (d, J=9.0 Hz, 1 H), 6.24 (d, J=6.0 Hz, 1 H), 5.93 (d, J=9.0 Hz, 1 H), 5.50 (d, J=6.0 Hz, 1 H), 5.33 (t, J=7.5 Hz, 1 H), 4.53 (s, 2 H), 4.31 (s, 1 H), 4.25 (s, 2 H), 3.73 (s, 2 H), 3.24 (s, 9 H), 2.39 (t, J=7.5 Hz, 2 H), 2.29 (t, J=7.5 Hz, 2 H), 1.63-1.56 (m, 5 H), 1.26 (br, 48H), 0.86 ppm (d, J=6.0 Hz, 6H); ¹³C NMR (75 MHz; CDCl₃/CD₃OD 1:1): δ =172.9, 172.6, 165.3, 151.0, 141.1, 109.4, 102.9, 85.9, 82.4, 73.2, 71.3, 66.5, 65.1, 59.6, 54.3, 33.6, 31.8, 29.6, 29.5, 29.4, 29.2, 29.0, 24.5, 22.5, 13.7 ppm; ³¹P NMR (121 MHz; CDCl₃/CD₃OD 1:1): $\delta = -0.9707$ ppm; IR (NaCl): $\tilde{\nu} = 3452$, 1733, 1652, 1456, 772 cm⁻¹; MS-FAB (*m/z*): found 886.59 [*M*+H]⁺; C₄₆H₈₄N₃O₁₁P calcd 886.58; HRMS-FAB (*m/z*): found 886.5922 [*M*+H]⁺; C₄₆H₈₃N₃O₁₁P calcd 886.5922.

5'-O-*Phosphatidylcholine-2'*,3'-O-*distearoyluridine* (**7***e*): Yield: 58%. m.p. >103.2 °C (dec.); ¹H NMR (300 MHz; CDCl₃/CD₃OD 1:1): δ = 7.87 (d, *J* = 9.0 Hz, 1 H), 6.19 (d, *J* = 6.0 Hz, 1 H), 5.99 (d, *J* = 9.0 Hz, 1 H), 5.45 (t, *J* = 3.0 Hz, 1 H), 5.28 (t, *J* = 6.0 Hz, 1 H), 4.99 (s, 2 H), 4.27 (s, 1 H), 4.21 (s, 2 H), 3.69 (s, 2 H), 3.19 (s, 9 H), 2.35 (t, *J* = 7.5 Hz, 2 H), 2.25 (t, *J* = 7.5 Hz, 2 H), 1.59–1.51 (m, 5 H), 1.22 (br, 56 H), 0.83 ppm (d, *J* = 6.0 Hz, 6 H); ¹³C NMR (75 MHz; CDCl₃/CD₃OD 1:1): δ = 173.6, 173.3, 165.9, 151.7, 141.8, 103.5, 86.5, 83.0, 73.8, 72.0, 67.3, 65.8, 60.4, 54.9, 34.3, 32.5, 30.3, 30.2, 30.1, 29.9, 29.8, 29.7, 25.4, 25.2, 23.2, 14.3 ppm; ³¹P NMR (121 MHz; CDCl₃/CD₃OD 1:1): δ = 1.7925 ppm; IR (NaCl): $\hat{\nu}$ = 3409, 2916, 2849, 1692, 1467, 1252 cm⁻¹; MS-FAB (*m*/*z*): found 942.65 (*M*+H]⁺; C₅₀H₉₂N₃O₁₁P calcd 942.65; HRMS-FAB (*m*/*z*): found 942.6550 [*M*+H]⁺; C₅₀H₉₂N₃O₁₁P calcd 942.6548.

Adenosine-based Phospholipids

5'-O-(4-Methoxytrityl)adenosine (2): MMTr-Cl (2.14 g, 6.31 mmol) was added to a solution of adenosine (1.30 g, 4.86 mmol) in dry pyridine (60 mL) and the mixture was stirred at room temperature for 20 h. The solvent was evaporated under high vacuum, and the resultant oil was dissolved in CH₂Cl₂ and then washed with water. The organic layer was dried over anhydrous Na₂SO₄. Chromatographic purification (SiO₂; CH₂Cl₂/MeOH 50:1) yielded **2** (1.62 g, 62%). m.p. 159–160 °C; ¹H NMR (300 MHz, CDCl₃): δ = 8.09 (s, 1H), 8.02 (s, 1H), 7.26–7.08 (m, 14H), 6.67 (d, *J* = 8.3 Hz, 2H), 5.89 (d, *J* = 3.9 Hz, 1H), 5.19 (m, 1H), 4.46 (m, 1H), 4.29 (m, 1H), 3.65 (s, 3H), 3.25 ppm (m, 2H); ¹³C NMR (75 MHz, CDCl₃): δ = 159.0, 156.1, 152.9, 149.3, 144.4, 144.3, 139.3, 135.5, 130.8, 128.8, 128.2, 127.4, 119.8, 113.5, 89.7, 87.3, 84.6, 75.45, 71.0, 63.5, 55.5 ppm; IR (NaCl): $\tilde{\nu}$ = 3353, 2926, 2855, 1665, 1605, 1443 cm⁻¹; MS-FAB (*m/z*): found 540.00 [*M*+H]⁺; C₃₀H₂₉N₅O₅ calcd 539.22.

2',3'-O-Didecanoyladenosine (5 a)—General Procedure: Decanoic acid (1.13 g, 7.87 mmol) was added to a solution of 2 (1.70 g, 3.15 mmol), EDC (1.51 g, 7.87 mmol), and DMAP (461 mg, 3.78 mmol) in dry CH₂Cl₂ (40 mL). The mixture was stirred at room temperature for 4 h and was then extracted with water and concentrated to dryness. The residue was dissolved in acetic acid (80%, 50 mL) and was then heated at 60 °C for 3 h. The reaction mixture was washed with water and CH₂Cl₂, and the organic layer was separated, dried (Na₂SO₄), and then evaporated under reduced pressure. Column chromatographic purification (SiO₂; CH₂Cl₂/MeOH 60:1) afforded **5a** (1.60 g, 95%). m.p. 150–151°C; ¹H NMR (300 MHz, CDCl₃): $\delta = 8.34$ (s, 1 H), 7.82 (s, 1 H), 6.75 (d, J = 9.2 Hz, 1H), 6.00 (m, 2H), 5.71 (m, 1H), 4.34 (m, 1H), 3.96 (m, 2H), 2.40 (t, J=7.4 Hz, 2H), 2.24 (t, J=7.4 Hz, 2H), 1.66 (br, 2H), 1.52 (br, 2H), 1.32-1.23 (br, 24 H), 0.90-0.84 ppm (br, 6 H); ¹³C NMR (75 MHz, $CDCl_3$): $\delta = 173.1$, 172.4, 156.8, 153.5, 149.4, 140.7, 121.8, 89.2, 87.2, 73.4, 73.2, 63.2, 34.8, 34.3, 32.5, 32.5, 30.1, 30.0, 29.9, 29.9, 29.9, 29.8, 29.8, 29.7, 25.6, 25.3, 23.3, 23.3, 14.7 ppm; IR (NaCl): $\tilde{v} = 3442$, 2923, 2851, 1742, 1641 cm⁻¹; MS-FAB (*m/z*): found 576.20 [*M*+H]⁺; $C_{30}H_{49}N_5O_6$ calcd 575.37.

2',3'-O-Dilauroyladenosine (**5**b): Yield: 88%. m.p. 148–149°C; ¹H NMR (300 MHz, CDCl₃): δ = 8.36 (s, 1H), 7.81 (s, 1H), 6.70 (d, *J* = 10.3 Hz, 1H), 6.06–5.98 (m, 2H), 5.89 (s, 2H), 5.71 (m, 1H), 4.35 (s, 1H), 4.01–3.82 (m, 2H), 2.40 (t, *J*=7.4 Hz, 2H), 2.24 (t, *J*=7.3 Hz, 2H), 1.89 (s, 1H), 1.66 (m, 2H), 1.52 (m, 2H), 1.27–1.22 (br, 32H), 0.89–0.85 ppm (br, 6H); ¹³C NMR (75 MHz, CDCl₃): δ = 173.2, 172.5, 156.7, 153.4, 149.3, 140.7, 121.7, 89.2, 87.2, 73.3, 73.2, 63.2, 34.8, 34.3, 32.5, 30.2, 30.1, 30.0, 29.9, 29.8, 29.8, 29.6, 25.5, 25.2, 23.3, 14.7 ppm; IR (NaCl): $\tilde{\nu} = 3423$, 2924, 2852, 1733, 1653 cm⁻¹; MS-FAB (*m/z*): found 632.20 [*M*+H]⁺; C₃₄H₅₇N₅O₆ calcd 631.43.

2',3'-O-Dimyristoyladenosine (**5** c): Yield: 98%. m.p. 147–148°C; ¹H NMR (300 MHz, CDCl₃): δ = 8.31 (s, 1H), 7.79 (s, 1H), 6.70 (d, *J* = 10.2 Hz, 1 H), 6.06 (s, 2H), 6.02–5.96 (m, 2H), 5.71 (m, 1 H), 4.37 (m, 1 H), 3.98–3.85 (m, 2H), 2.37 (t, *J* = 7.5 Hz, 2H), 2.21 (t, *J* = 7.3 Hz, 2 H), 1.64 (m, 2 H), 1.49 (m, 2 H), 1.29–1.20 (br, 40 H), 0.87–0.82 ppm (br, 6H); ¹³C NMR (75 MHz, CDCl₃): δ = 172.8, 172.1, 156.4, 153.1, 140.3, 121.4, 88.8, 86.9, 73.0, 72.9, 62.9, 34., 34.02, 32.2, 30.0, 29.9, 29.9, 29.8, 29.7, 29.6, 29.5, 29.5, 29.3, 24.9, 22.9, 14.4 ppm; IR (NaCl): $\tilde{\nu}$ = 3439, 2920, 2858, 1745, 1652 cm⁻¹; MS-FAB (*m/z*): found 688.30 [*M*+H]⁺; C₃₈H₆₅N₅O₆ calcd 687.49.

2',3'-O-Dipalmitoyladenosine (**5***d*): Yield: 85%. m.p. 140–141°C; ¹H NMR (300 MHz, CDCl₃): δ = 7.80 (s, 1H), 6.72 (s, 1H), 6.16 (d, *J* = 10.2 Hz, 1 H), 5.47 (m, 2 H), 5.25 (s, 2 H), 5.16 (m, 1 H), 3.80 (m, 1 H), 3.42–3.32 (m, 2 H), 1.85 (t, *J* = 7.4 Hz, 2 H), 1.67 (t, *J* = 7.6 Hz, 2 H), 1.26 (s, 1 H), 1.17 (m, 2 H), 0.98 (m, 2 H), 0.77–0.68 (br, 48 H), 0.35– 0.31 ppm (br, 6 H); ¹³C NMR (75 MHz, CDCl₃): δ = 173.1, 172.4, 156.6, 153.5, 140.3, 121.4, 89.3, 87.3, 78.1, 73.2, 63.3, 34.8, 34.3, 32.6, 30.3, 30.3, 30.2, 30.1, 30.0, 29.9, 29.8, 29.7, 25.6, 25.3, 23.3, 14.7 ppm; IR (NaCl): $\tilde{\nu}$ = 3438, 2925, 2855, 1747, 1640 cm⁻¹; MS-FAB (*m*/*z*): found 744.40 [*M*+H]⁺; C₄₂H₇₃N₅O₆ calcd 743.56.

2',3'-O-Distearoyladenosine (**5***e*): Yield: 81.5%. m.p. 141–142°C; ¹H NMR (300 MHz, CDCl₃): $\delta = 8.35$ (s, 1 H), 7.98 (s, 1 H), 6.70 (d, J = 10.7 Hz, 1 H), 6.00 (s, 2 H), 5.73 (m, 2 H), 4.35 (m, 1 H), 4.01–3.86 (m, 2 H), 2.40 (t, J = 7.4 Hz, 2 H), 2.24 (t, J = 7.4 Hz, 2 H), 1.69 (m, 2 H), 1.52 (m, 2 H), 1.25 (br, 56 H), 0.86 ppm (m, 6 H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 173.6$, 172.8, 157.06, 153.9, 149.7, 141.2, 122.3, 89.8, 87.8, 78.5, 73.7, 63.7, 35.2, 34.7, 33.0, 30.8, 30.7, 30.6, 30.5, 30.4, 30.3, 30.3, 30.1, 26.0, 25.7, 23.8, 15.2 ppm; IR (NaCl): $\hat{v} = 3430$, 2916, 2849, 1740, 1646 cm⁻¹; MS-FAB (*m/z*): found 800.30 [*M*+H]⁺; C₄₆H₈₁N₅O₆ calcd 799.62.

5'-O-Phosphatidylcholine-2',3'-O-didecanoyladenosine (8 a)—General Procedure: 2-Chloro-1,3,2-dioxaphospholane (158 µL, 1.78 mmol) was added to a solution of 5a (620 mg, 1.19 mmol) and diisopropylethylamine (248 µL, 1.42 mmol) in dry THF (20 mL), and the mixture was then stirred for 15 min at room temperature. Br_{2} (183 $\mu\text{L},$ 3.57 mmol) in dry THF (20 mL) was then slowly added with stirring at 0°C for 1 h. The solvents were evaporated, and the residue was dissolved in CHCl₃/iPrOH/CH₃CN (3:5:5). Aqueous trimethylamine (40%, 10 mL) was added, the mixture was stirred for 3 days at room temperature, and the solvents were then evaporated. Purification was accomplished by flash column chromatography (CH₂Cl₂/MeOH/H₂O 14:5:0.1 to 140:55:8). Removal of silica gel was accomplished by filtration through celite, and the solvent was then evaporated to afford 8a (260 mg, 29.4%). m.p. 240-241 °C; ¹H NMR (300 MHz, CD₃COOD): $\delta =$ 11.56 (s, 2 H), 8.66 (s, 1 H), 8.39 (s, 1 H), 6.44 (d, J=6.5 Hz, 1 H), 5.73 (m, 1 H), 5.71 (m, 1 H), 4.56-4.51 (m, 3 H), 4.35 (s, 2 H), 3.77 (s, 2 H), 2.28 (s, 9 H), 2.49 (t, J=7.0 Hz, 2 H), 2.31 (t, J=7.0 Hz, 2H), 1.72 (m, 2H), 1.55 (m, 2H), 1.34-1.27 (br, 24 H), 0.93 ppm (m, 6H); ^{13}C NMR (75 MHz, CD₃COOD): $\delta\!=\!173.2,$ 172.7, 153.9, 149.7, 148.9, 140.9, 117.9, 85.86, 83.1, 83.0, 74.6, 71.7, 66.5, 65.3, 59.9, 54.2, 33.9, 33.6, 31.9, 30.0, 29.6, 29.5, 29.4, 29.3, 29.2, 29.0, 24.9, 24.6, 22.69, 20.0, 13.6 ppm; ³¹P NMR (121 MHz; CDCl₃/CD₃OD 1:1): δ = 1.8332 ppm; IR (NaCl): $\tilde{\nu}$ = 3428, 2923, 2853, 1747, 1643 cm⁻¹; HRMS-FAB (*m*/*z*): found 741.4316 [*M*+H]⁺; $C_{35}H_{62}N_6O_9P$ calcd 741.4316.

5'-O-Phosphatidylcholine-2',3'-O-dilauroyladenosine (**8** b): Yield: 33 %. m.p. 239–240 °C; ¹H NMR (300 MHz, CD₃COOD): δ = 11.57 (s, 2 H), 8.68 (s, 1 H), 8.41 (s, 1 H), 6.45 (d, J = 6.7 Hz, 1 H), 5.79 (m, 2 H), 5.72 (m, 1 H), 4.57–4.52 (m, 3 H), 4.36 (s, 2 H), 3.78 (s, 2 H), 3.29 (s, 9 H), 2.50 (t, J = 7.3 Hz, 2 H), 2.32 (t, J = 7.2 Hz, 2 H), 1.73 (m, 2 H), 1.56 (m, 2 H), 1.34–1.29 (br, 32 H), 0.94 ppm (m, 6 H); ¹³C NMR (75 MHz, CD₃COOD): $\delta = 173.1$, 172.6, 153.6, 149.4, 141.0, 140.9, 117.9, 85.8, 83.0, 74.5, 71.6, 66.4, 65.2, 59.8, 54.1, 33.5, 33.5, 31.9, 29.9, 29.7, 29.6, 29.5, 29.4, 29.3, 29.2, 29.0, 24.8, 24.6, 22.6, 13.5 ppm; ³¹P NMR (121 MHz; CDCl₃/CD₃OD 1:1): $\delta = 1.8615$; IR (NaCl): $\tilde{\nu} = 3426$, 2922, 2852, 1741, 1643 cm⁻¹; HRMS-FAB (*m*/*z*): found 797.4940 [*M*+H]⁺; C₃₉H₂₀N₆O₉P calcd 797.4942.

5'-O-*Phosphatidylcholine-2'*,3'-O-*dimyristoyladenosine* (**8** c): Yield: 28%. m.p. 246–247 °C; ¹H NMR (300 MHz, CD₃COOD): δ = 11.47 (s, 2H), 8.66 (s, 1H), 6.44 (d, *J* = 6.6 Hz, 1H), 5.77 (m, 1H), 5.71 (m, 1H), 4.55 (m, 3H), 4.35 (s, 2H), 3.76 (s, 2H), 3.28 (s, 9H), 2.49 (t, *J* = 7.4 Hz, 2H), 2.31 (t, *J* = 7.4 Hz, 2H), 1.72 (m, 2H), 1.55 (m, 2H), 1.31– 1.28 (m, 40H), 0.95–0.93 ppm (m, 6H); ¹³C NMR (75 MHz, CD₃COOD): δ = 173.1, 172.7, 153.6, 149.6, 141.0, 140.7, 117.5, 85.8, 83.0, 74.5, 71.6, 66.4, 65.2, 59.8, 54.1, 33.8, 33.5, 31.9, 29.7, 29.4, 29.0, 24.9, 24.6, 22.6, 13.5 ppm; ³¹P NMR (121 MHz; CDCl₃/CD₃OD 1:1): δ = 1.8497 ppm; IR (NaCl): $\tilde{\nu}$ = 3443, 2923, 2854, 1738, 1644 cm⁻¹; HRMS-FAB (*m/z*): found 853.5570 [*M*+H]⁺; C₄₃H₇₈N₆O₉P calcd 853.5568.

5'-O-Phosphatidylcholine-2',3'-O-dipalmitoyladenosine (8 d): Yield: 22%. m.p. 235–236°C; ¹H NMR (300 MHz, CD₃COOD): δ = 8.61 (s, 1H), 8.35 (s, 1H), 6.38 (d, *J* = 6.2 Hz, 1H), 5.72 (m, 1H), 4.49 (m, 3 H), 4.29 (s, 2H), 3.70 (s, 2H), 3.22 (s, 9H), 2.43 (t, *J* = 6.9 Hz, 2H), 2.26 (t, *J* = 6.9 Hz, 2H), 1.66 (m, 2H), 1.50 (m, 2H), 1.26 (br, 48 H), 0.87 ppm (m, 6H); ¹³C NMR (75 MHz, CD₃COOD): δ = 173.1, 172.6, 153.5, 149.2, 148.9, 141.1, 117.8, 85.9, 83.1, 82.9, 74.5, 71.6, 66.4, 65.2, 59.9, 54.1, 33.8, 33.5, 31.9, 29.7, 29.6, 29.6, 29.5, 29.4, 29.3, 29.3, 29.2, 29.0, 24.8, 24.6, 22.6, 13.5 ppm; ³¹P NMR (121 MHz; CDCl₃/ CD₃OD 1:1): δ = 1.8413 ppm; IR (NaCl): $\tilde{\nu}$ = 3433, 2917, 2849, 1747, 1644 cm⁻¹; HRMS-FAB (*m*/*z*): found 909.6198 [*M*+H]⁺; C₄₇H₈₆N₆O₉P calcd 909.6194.

5'-O-*Phosphatidylcholine-2',3*'-O-*distearoyladenosine* (8 e): Yield: 18.6%. m.p. 238–239 °C; ¹H NMR (300 MHz, CD₃COOD): δ = 11.74 (s, 2H), 8.61 (s, 1H), 8.34 (s, 1H), 6.38 (d, *J* = 6.6 Hz, 1H), 5.71 (m, 1H), 5.65 (m, 1H), 4.51 (m, 3H), 4.30 (s, 2H), 3.71 (s, 2H), 3.22 (s, 9H), 2.43 (t, *J* = 7.5 Hz, 2H), 2.25 (t, *J* = 7.4 Hz, 2H), 1.66 (m, 2H), 1.49 (m, 2H), 1.26–1.22 (br, 56H), 0.87 ppm (m, 6H); ¹³C NMR (75 MHz, CD₃COOD): δ = 173.8, 172.8, 153.8, 149.7, 148.5, 141.2, 117.7, 85.3, 83.2, 82.7, 76.8, 74.3, 71.5, 66.5, 65.3, 59.8, 54.2, 33.8, 33.5, 31.8, 29.6, 29.5, 29.5, 29.4, 29.2, 29.2, 29.1, 28.9, 24.7, 24.5, 22.5, 20.3, 20.0, 13.7 ppm; ³¹P NMR (121 MHz; CDCl₃/CD₃OD 1:1): δ = 1.8856 ppm; IR (NaCl): $\tilde{\nu}$ = 3430, 2916, 2849, 1747, 1646 cm⁻¹; HRMS-FAB (*m/z*): found 965.6820 [*M*+H]⁺; C₅₁H₉₃N₆O₉P calcd 965.6820.

Inosine-based Phospholipids

5'-O-(4-Methoxytrityl)inosine (**3**): MMTr-Cl (2.96 g, 9.60 mmol) was added to a solution of inosine (2.15 g, 8.00 mmol) in dry pyridine/DMSO (1:1, 50 mL), and the mixture was stirred at room temperature for 18 h. The solvent was evaporated under high vacuum, and residual DMSO was removed by extraction with water and CH₂Cl₂. The organic layer was dried (Na₂SO₄) and concentrated to dryness. Column chromatographic purification (SiO₂; CH₂Cl₂/MeOH 50:1) yielded **3** (2.00 g, 74%). m.p. 208.8–210.1 °C; ¹H NMR (300 MHz; CDCl₃/CD₃OD 5:1): δ = 7.84 (s, 1H), 7.67 (s, 1H), 7.18 (d, *J* = 7.02 Hz, 1H), 7.08–6.94 (m, 8H), 6.58 (d, *J* = 9.1 Hz, 2H), 5.80 (d, *J* = 5.2 Hz, 1H), 4.48 (t, *J* = 5.1 Hz, 1H), 4.18 (t, *J* = 4.6 Hz, 1H), 4.04 (q, *J* = 3.9 Hz, 1H), 3.54 (s, 3 H), 3.24–3.12 ppm (m, 2H); ¹³C NMR (75 MHz; CDCl₃/CD₃OD 5:1): δ = 159.3, 158.2, 149.1, 145.7, 144.7, 144.7,

139.4, 135.9, 130.9, 129.0, 128.3, 127.5, 125.6, 113.7, 89.5, 87.4, 84.9, 75.2, 71.5, 64.2, 55.6 ppm; MS-FAB (*m*/*z*): 541.1 [*M*+H]⁺.

2',3'-O-Didecanoylinosine (6a)-General Procedure: Decanoic acid (798 mg, 4.63 mmol) was added to a solution of 3 (1.00 g, 1.85 mmol), EDC (888 mg, 24.6 mmol), and DMAP (271 mg, 2.20 mmol) in dry CH₂Cl₂ (40 mL). The mixture was stirred at room temperature for 4 h and was then extracted with water and concentrated to dryness. The residue was dissolved in acetic acid (80%, 50 mL) and was then heated at 60 $^{\circ}\mathrm{C}$ for 3 h. The reaction mixture was washed with water and $\mathsf{CH}_2\mathsf{Cl}_{2^{\prime}}$ the organic layer was separated and dried (Na2SO4), and the solvent was evaporated under reduced pressure. Column chromatographic purification (SiO₂; CH₂Cl₂/MeOH 60:1) afforded **6a** (897 mg, 84%). m.p. 169.7-171.9°C; ¹H NMR (300 MHz, CDCl₃): $\delta = 13.21$ (s, 1 H), 8.52 (s, 1 H), 8.05 (s, 1 H), 6.06 (d, J=7.5 Hz, 1 H), 5.94 (t, J=5.4 Hz, 1 H), 5.69 (d, J=5.3 Hz, 1 H), 4.35 (s, 1 H), 3.98 (t, J=15.3 Hz, 2 H), 2.40 (t, J= 7.5 Hz, 2 H), 2.26 (t, J=7.4 Hz, 2 H), 1.64 (br, 2 H), 1.53 (br, 2 H), 1.32-1.22 (m, 24 H), 0.90-0.82 ppm (m, 6 H); ¹³C NMR (75 MHz, CDCl₃): δ = 172.7, 172.0, 158.4, 148.0, 146.5, 140.0, 126.2, 88.1, 86.2, 73.3, 72.4, 62.5, 34.2, 33.7, 32.0, 31.9, 29.5, 29.5, 29.4, 29.4, 29.3, 29.3, 29.1, 25.0, 24.7, 22.8, 22.7 14.2 ppm; MS-FAB (m/z): 599.3 $[M+H]^+$; elemental analysis calcd (%) for $C_{30}H_{48}N_4O_7$: C 62.48, H 8.39, N 9.71; found C 62.54, H 8.21, N 9.80.

2',3'-O-Dilauroylinosine (**6b**): Yield: 87%. m.p. 164.0–165.9°C; ¹H NMR (300 MHz, CDCl₃): δ = 8.38 (s, 1 H), 7.97 (s, 1 H), 6.03 (d, J = 7.5 Hz, 1 H), 5.94 (t, J = 5.4 Hz, 1 H), 5.68 (d, J = 5.4 Hz, 1 H), 4.36 (s, 1 H), 3.95 (dd, J₁ = 19.5 Hz, J₂ = 12.0 Hz, 2 H), 2.41 (t, J = 7.4 Hz, 2 H), 2.26 (t, J = 7.4 Hz, 2 H), 1.65 (br, 2 H), 1.54 (br, 2 H), 1.33–1.24 (m, 32 H), 0.91–0.85 (m, 6 H) ppm; ¹³C NMR (75 MHz, CDCl₃): δ = 172.7, 172.0, 158.7, 148.0, 145.9, 140.1, 126.8, 88.5, 86.3, 73.2, 72.4, 62.7, 34.3, 33.8, 32.1, 29.8, 29.7, 29.6, 29.5, 29.4, 29.4, 29.2, 25.1, 24.8, 22.8, 14.2 ppm; IR (NaCl): $\tilde{\nu}$ = 3468, 2923, 2853, 1743, 1719, 1595, 1555, 1467, 1422, 1162 cm⁻¹; MS-FAB (*m*/z): 655.4 [*M*+Na]⁺; elemental analysis calcd (%) for C₃₄H₅₆N₄O₇: C 64.53, H 8.92, N 8.85; found C 64.74, H 8.72, N 8.76.

2',3'-O-Dimyristoylinosine (**6**c): Yield: 77%. m.p.: 162.2-163.6°C; ¹H NMR (300 MHz, CDCl₃): δ =12.94 (s, 1H), 8.36 (s, 1H), 7.98 (s, 1H), 6.01 (d, J=7.6 Hz, 1H), 5.91 (t, J=5.4 Hz, 1H), 5.66 (d, J= 5.2 Hz, 1H), 4.33 (s, 1H), 3.92 (dd, J₁=19.7 Hz, J₂=12.5 Hz, 2H), 2.38 (t, J=7.4 Hz, 2H), 2.23 (t, J=7.4 Hz, 2H), 1.64 (br, 2H), 1.51 (br, 2H), 1.24 (br, 40H), 0.86-0.82 ppm (m, 6H); ¹³C NMR (75 MHz; CDCl₃/CD₃OD 5:1): δ =172.8, 172.2, 157.5, 147.8, 145.6, 139.6, 126.0, 88.6, 85.7, 73.4, 72.1, 62.1, 34.1, 33.7, 31.9, 29.6, 29.5, 29.4, 29.3, 29.2, 29.2, 29.0, 24.9, 24.6, 22.6, 14.0 ppm; MS-FAB (m/z): 689.2 [*M*+H]⁺; elemental analysis calcd (%) for C₃₈H₆₄N₄O₇: C 66.25, H 9.36, N 8.13; found C 66.44, H 9.38, N 8.09.

2',3'-O-Dipalmitoylinosine (**6***d*): Yield: 85%. m.p. 160.6–163.9°C; ¹H NMR (300 MHz; CDCl₃/CD₃OD 5:1): δ = 13.15 (s, 1H), 8.47 (s, 1H), 8.01 (s, 1H), 6.05 (d, *J*=7.5 Hz, 1H), 5.94 (t, *J*=5.4 Hz, 1H), 5.70 (d, *J*=5.1 Hz, 1H), 4.36 (s, 1H), 3.96 (dd, *J*₁=18.9 Hz, *J*₂=12.3 Hz, 2H), 2.41 (t, *J*=7.5 Hz, 2H), 2.26 (t, *J*=7.5 Hz, 2H), 1.66 (br, 2H), 1.53 (br, 2 H), 1.33–1.23 (m, 48 H), 0.89–0.85 ppm (m, 6H); ¹³C NMR (75 MHz; CDCl₃/CD₃OD 5:1): δ =172.8, 172.2, 157.4, 147.8, 145.5, 139.6, 126.2, 87.7, 85.7, 73.4, 72.1, 62.2, 34.1, 33.7, 31.9, 29.7, 29.7, 29.5, 29.5, 29.4, 29.3, 29.2, 29.1, 25.0, 24.7, 22.7, 14.0 ppm; MS-FAB (*m*/z): 745.4 [*M*+H]⁺; elemental analysis calcd (%) for C₄₂H₇₂N₄O₇: C 67.71, H 9.74, N 7.52; found: C 67.88, H 9.79, N 7.32.

5'-O-Phosphatidylcholine-2',3'-O-didecanoylinosine (**9***a*)—General Procedure: 2-Chloro-1,3,2-dioxaphospholane (117 μ L, 1.31 mmol) was added to a solution of **6***a* (500 mg, 0.87 mmol) and diisopropylethylamine (303 μ L, 1.74 mmol) in dry THF (20 mL), and the mix-

CHEMBIOCHEM

ture was then stirred for 15 min at room temperature. Br_2 (130 $\mu\text{L},$ 2.61 mmol) in dry THF (20 mL) was then slowly added with stirring at 0°C for 1 h. The solvent was evaporated, and the residue was dissolved in CHCl₃/iPrOH/CH₃CN (3:5:5). Aqueous trimethylamine (40%, 10 mL) was added, the mixture was stirred for 3 days at room temperature, and the solvents were evaporated. Purification was accomplished by flash chromatography (SiO₂; CH₂Cl₂/MeOH/ H₂O 14:5:0.1 to 140:55:8). Removal of silica gel was accomplished by filtration through celite, and the solvent was then evaporated to afford **9a** (173 mg, 27%). m.p. >197.0°C (dec.); ¹H NMR (300 MHz; CDCl₃/CD₃COOD 5:1): δ = 8.54 (s, 1 H), 8.21 (s, 1 H), 6.28 (d, J=6.1 Hz, 1 H), 5.83 (t, J=5.7 Hz, 1 H), 5.67 (m, 1 H), 4.46 (br, 3 H), 4.30 (br, 2 H), 3.70 (br, 2 H), 3.23 (s, 9 H), 2.43 (t, J=7.2 Hz, 2 H), 2.30 (t, J=7.4 Hz, 2 H), 1.67 (br, 2 H), 1.54 (br, 2 H), 1.26 (m, 24 H), 0.88 ppm (m, 6H); ¹³C NMR (75 MHz; CDCl₃/CD₃COOD 5:1): $\delta =$ 173.1, 172.8, 158.9, 149.4, 146.0, 140.2, 123.9, 86.6, 83.3, 74.6, 71.8, 68.0, 66.9, 65.1, 60.0, 54.8, 34.3, 34.1, 32.2, 29.8, 29.8, 29.7, 29.6, 29.6, 29.5, 29.4, 25.2, 25.0, 22.3, 14.2 ppm; ³¹P NMR (121 MHz; CDCl₃/CD₃OD 5:1): $\delta = -0.1918$ ppm; MS-FAB (*m*/*z*): 742.2 [*M*+H]⁺; HRMS-FAB (m/z): found 742.4156 [M+H]⁺; C₃₅H₆₀N₅O₁₀P calcd 742.4156:.

5'-O-*Phosphatidylcholine-2'*,3'-O-*dilauroylinosine* (**9***b*): Yield: 15%. m.p. > 179.1 °C (dec.); ¹H NMR (300 MHz; CDCl₃/CD₃COOD 5:1): δ = 8.41 (s, 1 H), 8.08 (s, 1 H), 6.17 (d, *J* = 6.0 Hz, 1 H), 5.72 (t, *J* = 5.6 Hz, 1 H), 5.56 (br, 1 H), 4.34 (br, 3 H), 4.17 (br, 2 H), 3.56 (br, 2 H), 3.13 (s, 9 H), 2.32 (t, *J* = 7.2 Hz, 2 H), 2.19 (t, *J* = 7.3 Hz, 2 H), 1.54 (br, 2 H), 1.44 (br, 2 H), 1.17 (m, 32 H), 0.79 ppm (t, *J* = 5.4 Hz, 6 H); ¹³C NMR (75 MHz; CDCl₃/CD₃OD 5:1): δ = 173.0, 172.6, 158.7, 149.3, 145.9, 139.9, 123.9, 86.3, 83.1, 74.3, 71.6, 66.7, 65.0, 59.9, 54.6, 34.2, 33.9, 32.1, 29.8, 29.7, 29.7, 29.5, 29.5, 29.4, 29.3, 25.1, 24.8, 22.8, 14.1 ppm; ³¹P NMR (121 MHz; CDCl₃/CD₃OD 5:1): δ = 4.9022 ppm; MS-FAB (*m/z*): 798.3 [*M*+H]⁺; HRMS-FAB (*m/z*): found 798.4779 [*M*+H]⁺; C₃₉H₆₈N₅O₁₀P calcd 798.4782.

5'-O-*Phosphatidylcholine-2'*,3'-O-*dimyristoylinosine* (*9 c*): Yield: 20%. m.p. > 184.8 °C (dec.); ¹H NMR (300 MHz; CDCl₃/CD₃COOD 5:1): δ = 8.42 (s, 1 H), 8.11 (s, 1 H), 6.17 (d, *J*=6.1 Hz, 1 H), 5.72 (t, *J*=5.6 Hz, 1 H), 5.57 (m, 1 H), 4.35 (br, 3 H), 4.19 (br, 2 H), 3.60 (br, 2 H), 3.12 (s, 9 H), 2.33 (t, *J*=7.3 Hz, 2 H), 2.19 (t, *J*=7.3 Hz, 2 H), 1.54 (br, 2 H), 1.44 (br, 2 H), 1.17 (m, 40 H), 0.78 ppm (t, *J*=6.2 Hz, 6 H); ¹³C NMR (75 MHz; CDCl₃/CD₃OD 5:1): δ =173.2, 172.8, 158.9, 149.5, 146.3, 140.3, 124.0, 86.7, 83.3, 74.7, 71.9, 67.0, 65.3, 60.2, 54.8, 34.4, 34.1, 32.4, 30.1, 30.1, 30.0, 29.9, 29.8, 29.7, 29.7, 29.5, 29.3, 25.1, 23.1, 14.2 ppm; ³¹P NMR (121.50 Hz; CDCl₃/CD₃OD 5:1): δ =-0.2444 ppm; MS-FAB (*m/z*): 854.4 [*M*+H]⁺; HRMS-FAB (*m/z*): found 854.5412 [*M*+H]⁺; C₄₃H₇₆N₅O₁₀P calcd 854.5408.

5'-O-*Phosphatidylcholine-2',3*'-O-*dipalmitoylinosine* (*9 d*): Yield: 20%. m.p. > 195.0 °C (dec.); ¹H NMR (300 MHz; CDCl₃/CD₃COOD 5:1): δ = 8.53 (s, 1 H), 8.20 (s, 1 H), 6.27 (d, *J* = 6.2 Hz, 1 H), 5.83 (t, *J* = 5.6 Hz, 1 H), 5.67 (m, 1 H), 4.46 (br, 3 H), 4.30 (br, 2 H), 3.71 (br, 2 H), 3.23 (s, 9 H), 2.43 (t, *J* = 7.3 Hz, 2 H), 2.29 (t, *J* = 7.4 Hz, 2 H), 1.67 (br, 2 H), 1.54 (br, 2 H), 1.28 (m, 48 H), 0.88 ppm (t, *J* = 6.3 Hz, 6 H); ¹³C NMR (75 MHz; CDCl₃/CD₃COOD 5:1): δ = 173.1, 172.7, 158.9, 149.4, 146.0, 140.2, 123.9, 86.6, 83.2, 74.6, 71.8, 66.9, 65.2, 60.0, 54.7, 34.3, 34.1, 32.2, 30.0, 29.9, 29.8, 29.7, 29.6, 29.6, 29.4, 25.2, 25.0, 23.0, 14.1 ppm; ³¹P NMR (121 MHz; CDCl₃/CD₃OD 5:1): δ = −0.2332 ppm; MS-FAB (*m/z*): 910.5 [*M*+H]⁺; HRMS (*m/z*): found 910.6033 [*M*+H]⁺; C₄₉H₈₄N₅O₁₀P calcd 910.6034; elemental analysis calcd (%) for C₄₉H₈₄N₅O₁₀P: C 62.02, H 9.30, N 7.69; found C 62.16, H 9.02, N 7.38.

Acknowledgements

We are grateful to KISTEP for financial support through the National Research Laboratory Program (Laboratory for Modified Nucleic Acid Systems) and to the IMT-2000 (01-PJ11-PG9-01NT00-0031) program.

Keywords: liposomes · nucleosides · phospholipids · selfasssembly · supramolecular chemistry

- a) M. Ross, Vesicles, Marcel Dekker, New York, 1996; b) D. J. Hanhan, A Guide to Phospholipid Chemistry, Oxford University Press, New York, 1997; c) G. Cevc, Phospholipids Handbook, Marcel Dekker, New York, 1993.
- [2] a) K. Bandoh, J. Aoki, H. Hosono, S. Kobayashi, T. Kobayashi, K. Murakami-Murofushi, M. Tsijumoto, H. Arai, K. Inoue, J. Biol. Chem. 1999, 274, 27776–27785; b) G. Gueguen, B. Gaige, J. M. Grevy, P. Rogalle, J. Bellan, M. Wilson, A. Klaebe, F. Pont, M. F. Simon, H. Chap, Biochemistry 1999, 38, 8440–8450; c) T. Sugiura, S. Nakane, S. Kishimoto, K. Waku, Y. Yoshioka, A. Tokumura, D. J. Hanahan, Biochim. Biophys. Acta 1999, 1440, 194–204.
- [3] a) S. L. Morris-Natschke, F. Gumus, C. J. Marasco, Jr, K. L. Meyer, M. Marx, C. Piantadosi, M. D. Layne, E. J. Modest, J. Med. Chem. 1993, 36, 2018–2025; b) A. Wissner, R. E. Schaub, P. E. Sum, C. A. Kohler, B. M. Goldstein, J. Med. Chem. 1985, 28, 1181–1187; c) D. H. Thompson, C. B. Svendsen, C. D. Meglio, V. C. Anderson, J. Org. Chem. 1994, 59, 2945–2955; d) H. Eibl, Chem. Phys. Lipids 1980, 26, 405–429; e) R. Z. Zare, B. P. Modi, D. T. Chiu, O. Orwar, A. Mascho, Proc. Natl. Acad. Sci. USA 1996, 93, 11443–11447; f) F. Ramires, J. F. Marecek, Synthesis 1985, 449–488; g) F. M. Menger, Y. J. Wong, J. Org. Chem. 1996, 61, 7382–7390; h) L. Jan, E. Johan, K. Peter, J. Org. Chem. 2002, 67, 194–199; i) F. M. Menger, X. Y. Chen, Tetrahedron Lett. 1996, 37, 323–326; j) N. A. J. M. Sommerdijk, T. H. L. Hoeks, M. Synak, M. C. Feiters, R. J. M. Nolte, B. Zwanenburg, J. Am. Chem. Soc. 1997, 119, 4338–4344.
- [4] G. S. Hird, T. G. McIntosh, M. W. Grinstaff, J. Am. Chem. Soc. 2000, 122, 8097–8098.
- [5] L. Moreau, P. Barthelemy, M. E. Maataoui, M. W. Grinstaff, J. Am. Chem. Soc. 2004, 126, 7533–7539.
- [6] a) H. Yanagawa, Y. Ogawa, H. Furuta, K. Tsuno, *Chem. Lett.* **1988**, 269–272; b) H. Yanagawa, Y. Ogawa, H. Furuta, K. Tsuno, *Chem. Lett.* **1989**, 403–406; c) H. Yanagawa, Y. Ogawa, H. Furuta, K. Tsuno, *J. Am. Chem. Soc.* **1989**, 111, 4567–4570; d) Y. Itojima, Y. Ogawa, K. Tsuno, N. Honda, H. Yanagawa, *Biochemistry* **1992**, 31, 4757–4765.
- [7] S. Bonaccio, M. Wessicken, D. Berti, P. Walde, L. Luisi, *Langmuir* 1996, 12, 4976–4978.
- [8] a) G. S. Hird, T. G. McIntosh, A. A. Riberio, M. W. Grinstaff, J. Am. Chem. Soc. 2002, 124, 5983-5992; b) G. S. Hird, M. W. Grinstaff, Chem. Phys. Lipids 2002, 120, 1-7.
- [9] a) Y. R. Vandenburg, Z. Zhang, D. J. Fishkind, B. D. Smith, *Chem. Commun.* 2000, 149–150; b) G. Wang, R. I. Hollingsworth, *J. Org. Chem.* 1999, 64, 4140–4147; c) W. Srisiri, T. M. Sisson, D. F. O'Brien, *J. Am. Chem. Soc.* 1996, 118, 11327–11328; d) D. Kitamoto, S. Ghosh, G. Ourisson, Y. Nakatani, *Chem. Commun.* 2000, 861–862; e) T. Y. Ahmad, J. D. Morrisett, H. J. Pownall, A. M. Gotto, Jr., H. L. Brockman, H. Z. Sable, E. O. Lewis, A. J. Hancock, *Chem. Phys. Lipids* 1990, 55, 231–243; f) S. G. Batrakov, D. I. Nikitin, V. I. Sheichenko, A. O. Ruzhitsky, *Biochim. Biophys. Acta* 1997, 1347, 127–139.
- [10] We characterized the final products by HR-FAB mass spectrometry as well as by ¹H, ¹³C, and ³¹P NMR spectroscopy. Complete experimental details are available in the Supporting Information.
- [11] P. Walde, S. Ichikawa, Biomol. Eng. 2001, 18, 143-177.
- [12] F. M. Menger, M. I. Angelova, Acc. Chem. Res. **1998**, 31, 789-797.
- [13] M. J. Hope, M. B. Bally, G. Webb, P. R. Cullis, Biochim. Biophys. Acta 1985, 812, 55–65.
- [14] T. Kunitake, U. Okahata, J. Am. Chem. Soc. 1980, 102, 549-553.
- [15] The samples were stained with 2% (w/v) uranyl acetate solution.
- [16] a) F. O. David, A. Bruce, B. Alto, E. B. Doyle, G. L. Henry, Y. Lee, S. Warunee, M. S. Thomas, Acc. Chem. Res. 1998, 31, 861–868; b) S. M. Gruner,

Proc. Natl. Acad. Sci. USA 1985, 82, 3665-3669; c) S. M. Gruner, J. Phys. Chem. 1989, 93, 7562-7570.

- [17] S. Svetina, B. Zeks, Anat. Rec. 2002, 268, 215-225.
- [18] S. Koh, T. Tara, Y. Tetsuya, S. Tadashi, ChemBioChem 2003, 4, 778-781.
- [19] A. M. David, A. F. Gerg, *DNA Science*, Cold Spring Harbor Laboratory Press, New York, **2003**.

Received: September 10, 2004